AusBiotech 2012: Program now available for industry event of the year
04 September, 2012 by AusBiotechThe event, to be held in Melbourne – 30 October - 2 November 2012 – will feature expert speakers from overseas and Australia, who will speak on investment, public policy, industry experiences and business development.
Innate Immunotherapeutics to raise US$10m for Australian MS trial
03 September, 2012 by Dylan Bushell-EmblingNew Zealand's Innate Immunotherapeutics has launched a US$10 million ($9.75 million) capital raising to help fund an Australian trial of a prospective treatment for progressed multiple sclerosis.
Azure Healthcare swings to profit for FY12
03 September, 2012 by Dylan Bushell-EmblingAzure Healthcare (ASX:AZV), shed of its unprofitable audio visual business, swung to a $744,000 net profit for FY12.
GTG launches new patent infringement suit
31 August, 2012 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has filed a patent suit against California's Reproductive Genetics Institute, in the newest enforcement effort for its non-coding DNA patents.
UQ researchers get funding for plant antiviral
31 August, 2012 by Dylan Bushell-EmblingCommercialisation Australia has granted a $50,000 grant to help bring Nexgen – an anti-viral technology for plants developed at The University of Queensland – to market.
Productivity Commission reviews compulsory licensing in the patents system
30 August, 2012 by AusBiotechThe Productivity Commission’s review into compulsory licensing in the patents system is now examining whether and how to ensure access to patented technology, while maintaining the patent incentive to create and protect new technology.
Bluechiip secures supply deal with US CRO
29 August, 2012 by Dylan Bushell-EmblingTracking chip technology developer Bluechiip (ASX:BCT) has forged a strategic partnership with US CRO Gentris Corporation. Bluechiip has agreed to provide Gentris with its eponymous temperature sensing and tracking chips, which are initially being developed for cryogenic sample management.
Expert endorses Alchemia oncology spin-off
29 August, 2012 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has filed papers with ASIC regarding the proposed spin-off of its oncology business, after the independent analysts hired to assess the deal concluded that the demerger is in shareholders' best interests.
Sirtex FY12 profit grows nearly 50%
29 August, 2012 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) increased its FY12 profit by 49%, on the back of strong sales of its SIR-Spheres targeted radiation therapy treatments for liver cancer.
Quarterly payments for R&D Tax Incentive progress to consultation
28 August, 2012 by AusBiotechPlans are now progressing for the implementation of quarterly payments of the R&D Tax Incentive, to be accessible for each quarter commencing on or after 1 January 2014. In preparations, the Assistant Treasurer, the Hon David Bradbury and the Minister for Industry and Innovation, the Hon Greg Combet, have jointly released a public consultation paper on the design and implementation of the R&D quarterly credits.
Nanosonics triples revenue from Trophon EPR sales
27 August, 2012 by Dylan Bushell-EmblingStrong early sales of Nanosonics' (ASX:NAN) disinfection cabinets helped the company triple its revenue and cut its full-year losses by 58% in FY12.
MiReven gets extra $500k for microRNA cancer research
27 August, 2012 by Dylan Bushell-EmblingStart-up MiReven has received a $500,000 funding injection, after forging R&D partnerships and reaching internal milestones in efforts to develop cancer treatments based on a strain of microRNA.
Trial of NovoSorb hit with delays: Calzada
24 August, 2012 by Dylan Bushell-EmblingCalzada (ASX:CZD) has been forced to push back the planned completion date for a planned human clinical trial of its NovoSorb BTM burns treatment product until well into 2013.
Court calls meeting to vote on Alchemia spinoff
24 August, 2012 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has reached two new milestones in its efforts to spin off its oncology business into a separate company listed on the Nasdaq.
Patrys raises cash, shaves loss in FY12
23 August, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) ended FY12 in a more stable financial position, after raising enough cash to see it through until early 2014.
